INIS
patients
100%
stem cells
33%
diseases
31%
risks
30%
leukemia
23%
lymphomas
23%
blood
20%
comparative evaluations
20%
myeloid leukemia
18%
transplants
17%
therapy
16%
populations
14%
data
13%
levels
12%
mortality
11%
malignancies
10%
grafts
10%
adults
10%
doses
9%
cancer
9%
natural killer cells
9%
chemotherapy
9%
netherlands
8%
refractories
8%
host
8%
hazards
8%
cyclophosphamide
8%
hemophilia
7%
tumors
6%
glucose
6%
control
6%
humans
6%
receptors
6%
induction
6%
toxicity
6%
transfusions
6%
plasma
5%
symptoms
5%
quality of life
5%
sex
5%
Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
35%
Maastricht
20%
Acute Myeloid Leukemia
15%
Marrow Transplantation
12%
Type 2 Diabetes Mellitus (T2DM)
11%
Overall Survival
11%
Working Party
11%
Confidence Interval
10%
Natural Killer Cells
10%
Chronic Lymphocytic Leukemia
9%
Graft-versus-host Disease (GvHD)
9%
Netherlands
9%
Hazard Ratio
8%
Leukemia Patients
7%
Unrelated Donor
7%
Lymphoma
6%
Multiple Myeloma
6%
Non-relapse Mortality
6%
European Society
6%
Malignancy
5%
Acute Leukemia
5%
Progression-free Survival
5%
Hemophilia
5%
Post-transplantation Cyclophosphamide (PTCy)
5%
Myelodysplastic Syndrome
5%
Medicine and Dentistry
Hematopoietic Cell
14%
Transplantation
13%
Cell Transplantation
12%
Acute Myeloid Leukemia
11%
Overall Survival
11%
Maturity Onset Diabetes of the Young
9%
Disease
8%
B-Cell Chronic Lymphocytic Leukemia
8%
Chemotherapy
8%
Allogeneic Stem Cell Transplantation
7%
Hazard Ratio
6%
Autologous Stem Cell Transplantation
6%
Allogeneic Hematopoietic Stem Cell Transplantation
6%
Myelodysplastic Syndrome
6%
Cancer
6%
Progression Free Survival
5%
Cyclophosphamide
5%
Multiple Myeloma
5%